• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AVEO Oncology

    AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
    From AVEO Oncology
    Via Business Wire
    Tickers AVEO
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.